PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 11 August 1997, 6:00 a.m. EDT

"Many immunoassays to detect HIV and H. pylori infection require constant refrigeration, increasing overhead and limiting point-of-care usage. Extension of the shelf life of our rapid tests reflects the durability and stability of our products, enhancing our competitiveness in the marketplace," said SDS President and Chief Executive Officer Kenneth McLachlan. "The data apply to all of our HIV rapid tests, which use serum, whole blood or saliva for analysis. As we continue to collect data, we expect stability results to increase for our H. pylori test, as well.

"Having a longer shelf life makes it possible for our products to be ordered in larger quantities, since customers can expect the tests to perform even if they sit in customs or are in transit for extended periods. Because our tests are also fast, easy to use and do not require additional equipment," said McLachlan, "we believe they are extremely cost effective and attractive to customers, especially in areas where HIV and H. pylori infection are rampant."

Saliva Diagnostic Systems is a developer and manufacturer of rapid tests for infectious diseases and certain other conditions. The company is based in Vancouver, Washington with operations in Singapore and London. SDS products include a range of rapid tests to detect HIV antibodies that use serum, whole blood and saliva for analysis. The tests, which require only a few, simple steps to use, are designed to produce results within minutes without the use of special equipment, training or storage. The company has also developed a rapid blood test to detect Helicobacter pylori (a bacteria linked to peptic ulcers), and is in the process of creating rapid serum tests for Hepatitis A and Tuberculosis.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially include the following: changes in demand for the company's products, the ability of the company to increase manufacturing capacity, the ability of the company to obtain regulatory approvals, success in technological advances and their implementation, cost and yield issues associated with production, the ability of the company to raise additional capital, and other risk factors listed in the company's Amendment No. 1 to the Registration Statement dated June 13, 1997.

NOTE: For more information on Saliva Diagnostic Systems via fax at no cost, dial 800-PRO-INFO (908-544-2850 outside the U.S.), ticker symbol SALV.

SOURCE: Saliva Diagnostic Systems Inc.

Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
970811
PR970810

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .